A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor.

ABSTRACT:

Rationale

In 2015, a survey of cystic fibrosis (CF) physicians showed significant gaps in lung transplant (LTx) referral knowledge. Subsequently, LTx referral guidelines for people with CF were published, and elexacaftor/tezacaftor/ivacaftor (ETI) became available for >80% of people in the United States (US). We sought to assess physicians' LTx referral knowledge and self-reported referral practices.

Methods

CF center directors in the US were surveyed about LTx. Questions addressed transplant referral indications, contraindications, testing, and the impact of ETI on referral timing. Thematic analysis was used to assess responses to open-ended questions.

Results

There were 110/309 (36%) responses. Respondents identified several referral indications, including rapid dec

SUBMITTER: Burdis N 

PROVIDER: S-EPMC11602374 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature